AntriaBio Receives Notice of Allowance on Patent Covering Microsphere Drug Delivery Platform
November 17, 2015 08:30 ET
|
AntriaBio, Inc.
LOUISVILLE, CO--(Marketwired - November 17, 2015) - AntriaBio, Inc. ("AntriaBio" or the "Company") (OTCQB: ANTB), a biopharmaceutical corporation developing novel extended release therapies,...
AntriaBio Announces New Product Candidate, AB301, a Weekly GLP-1 Agonist and Basal Insulin Combination, for Type 2 Diabetes
September 16, 2015 07:30 ET
|
AntriaBio, Inc.
LOUISVILLE, CO--(Marketwired - September 16, 2015) - AntriaBio, Inc. ("AntriaBio" or the "Company") (OTCQB: ANTB), a biopharmaceutical corporation developing novel extended release therapies,...
AntriaBio Appoints David F. Welch, Ph.D. to Its Board of Directors
June 29, 2015 08:00 ET
|
AntriaBio, Inc.
LOUISVILLE, CO--(Marketwired - June 29, 2015) - AntriaBio, Inc. ("AntriaBio" or the "Company") (OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel extended release therapies,...
AntriaBio Announces Promising Preclinical Results for Once-Weekly Basal Insulin AB101
June 08, 2015 07:30 ET
|
AntriaBio, Inc.
LOUISVILLE, CO--(Marketwired - June 08, 2015) - AB101 drug substance retained similar receptor binding affinity and receptor-mediated biological activity compared to native insulinSingle dose...
AntriaBio to Present New Preclinical Data at the American Diabetes Association 75th Scientific Sessions
May 11, 2015 08:00 ET
|
AntriaBio, Inc.
LOUISVILLE, CO--(Marketwired - May 11, 2015) - AntriaBio, Inc. ("AntriaBio" or the "Company") (OTCQB: ANTB), a biopharmaceutical corporation developing novel extended release therapies, announced...
AntriaBio Announces Appointment of Dr. Hoyoung Huh as Chairman of Scientific Advisory Board and Business Development
January 08, 2015 07:35 ET
|
AntriaBio, Inc.
LOUISVILLE, CO and MENLO PARK, CA--(Marketwired - Jan 8, 2015) - AntriaBio, Inc. ("AntriaBio or the "Company") (OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel extended...
AntriaBio Announces Completion of PK/PD Studies of AB101 in Two Species
January 07, 2015 08:00 ET
|
AntriaBio, Inc.
LOUISVILLE, CO--(Marketwired - Jan 7, 2015) - AntriaBio, Inc. ("AntriaBio or the "Company") (OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel extended release therapies,...
AntriaBio Announces $7 Million Private Placement
January 05, 2015 07:35 ET
|
AntriaBio Inc.
LOUISVILLE, CO--(Marketwired - Jan 5, 2015) - AntriaBio, Inc. ("Company") (OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel extended release therapies, announced today that...
AntriaBio Extinguishes $44 Million Contingent Liability
November 10, 2014 08:05 ET
|
AntriaBio, Inc.
LOUISVILLE, CO--(Marketwired - Nov 10, 2014) - AntriaBio, Inc. (OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel extended release therapies, announced today that it has...
AntriaBio Appoints C. Ronald Kahn, M.D. to Its Scientific Advisory Board
June 23, 2014 07:35 ET
|
AntriaBio Inc.
MENLO PARK, CA--(Marketwired - Jun 23, 2014) - AntriaBio, Inc. (OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel therapeutics to treat patients with diabetes and metabolic...